BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND CALR, ENSG00000179218, 811, P27797, SSA, RO, FLJ26680, cC1qR AND Treatment
252 results:

  • 1. Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.
    Han R; Guo H; Shi J; Zhao S; Jia Y; Liu X; Liu Y; Cheng L; Zhao C; Li X; Zhou C
    BMC Med; 2024 Apr; 22(1):174. PubMed ID: 38658988
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell lung cancer.
    Mooradian MJ; Cai L; Wang A; Qiao Y; Chander P; Whitaker RM
    JAMA Netw Open; 2024 Apr; 7(4):e247542. PubMed ID: 38648057
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
    Leonetti A; Perrone F; Puntoni M; Maglietta G; Bordi P; Bria E; Vita E; Gelsomino F; De Giglio A; Gelibter A; Siringo M; Mazzoni F; Caliman E; Genova C; Bertolini F; Guaitoli G; Passiglia F; Delcuratolo MD; Montrone M; Cerea G; Pasello G; Roca E; Belluomini L; Cecere FL; Guida A; Manzo A; Adamo V; Rastelli F; Bulotta A; Citarella F; Toschi L; Zoratto F; Cortinovis DL; Berardi R; Follador A; Carta A; Camerini A; Salerno F; Silva RR; Baldini E; Cortellini A; Brighenti M; Santoni M; Malorgio F; Caminiti C; Tiseo M
    Eur J Cancer; 2024 May; 202():114006. PubMed ID: 38489861
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Prediction of Microwave Ablation Recurrence in Pulmonary Malignancies Using Preoperative Computed Tomography Radiomics Models.
    Zhu F; Yang C; Yang J; Mao H; Huang Y; Liu H; Zhao Z
    Curr Med Imaging; 2024; 20():1-26. PubMed ID: 38389378
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?
    Zhao Y; Mei T; Na F; Tian X; Ao R; Long X; Luo Q; Duan P; Zhu J; Wang Y; Huang M; Liu Y; Gong Y
    Invest New Drugs; 2024 Apr; 42(2):196-206. PubMed ID: 38386170
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis.
    Oliveira C; Mainoli B; Duarte GS; Machado T; Tinoco RG; Esperança-Martins M; Ferreira JJ; Costa J
    Eur J Clin Pharmacol; 2024 May; 80(5):677-684. PubMed ID: 38372756
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer.
    Lang C; Megyesfalvi Z; Lantos A; Oberndorfer F; Hoda MA; Solta A; Ferencz B; Fillinger J; Solyom-Tisza A; Querner AS; Egger F; Boettiger K; Klikovits T; Timelthaler G; Renyi-Vamos F; Aigner C; Hoetzenecker K; Laszlo V; Schelch K; Dome B
    World J Surg Oncol; 2024 Feb; 22(1):57. PubMed ID: 38369463
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients.
    Strosberg JR; Al-Toubah T; El-Haddad G; Reidy Lagunes D; Bodei L
    J Nucl Med; 2024 Mar; 65(3):340-348. PubMed ID: 38238038
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Developing a multi-institutional nomogram for assessing lung cancer risk in patients with 5-30 mm pulmonary nodules: a retrospective analysis.
    Jiang Y; Deng T; Huang Y; Ren B; He L; Pang M; Jiang L
    PeerJ; 2023; 11():e16539. PubMed ID: 38107565
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter chart review project.
    Bafaloukos D; Kouzis P; Gouveris P; Boukovinas I; Kalbakis K; Baka S; Kyriakakis G; Moschou D; Molfeta A; Demiri S; Mavroudis D; Spanoudi F; Dimitriadis I; Gogas H
    Melanoma Res; 2024 Apr; 34(2):152-165. PubMed ID: 38092014
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Pediatric pulmonary multisystem langerhans cell histiocytosis: does lung lesion severity affect the outcome?
    Sedky M; Gohar S; Ahmed S; Zaky I; Salama A; Hassanein O; Maher E; ElHaddad A
    Orphanet J Rare Dis; 2023 Nov; 18(1):361. PubMed ID: 37978394
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. [Anatomical resection for non-small cell lung cancer: cardiopulmonary exercise testing in assessing the risk of respiratory complications].
    Galkin VN; Esakov YS; Samsonik SA; Regushevskaya DV; Banova ZI; Giverts IY
    Khirurgiia (Mosk); 2023; (10):88-97. PubMed ID: 37916562
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell lung cancer: A Randomized Clinical Trial.
    Takahashi N; Hao Z; Villaruz LC; Zhang J; Ruiz J; Petty WJ; Mamdani H; Riess JW; Nieva J; Pachecho JM; Fuld AD; Shum E; Chauhan A; Nichols S; Shimellis H; McGlone J; Sciuto L; Pinkiert D; Graham C; Shelat M; Kattappuram R; Abel M; Schroeder B; Upadhyay D; Krishnamurthy M; Sharma AK; Kumar R; Malin J; Schultz CW; Goyal S; Redon CE; Pommier Y; Aladjem MI; Gore SD; Steinberg SM; Vilimas R; Desai P; Thomas A
    JAMA Oncol; 2023 Dec; 9(12):1669-1677. PubMed ID: 37824137
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan.
    Baba T; Kusumoto M; Kato T; Kurihara Y; Sasaki S; Oikado K; Saito Y; Endo M; Fujiwara Y; Kenmotsu H; Sata M; Takano T; Kato K; Hirata K; Katagiri T; Saito H; Kuwano K
    Int J Clin Oncol; 2023 Dec; 28(12):1585-1596. PubMed ID: 37787866
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Bintrafusp Alfa Versus Pembrolizumab in Patients With treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.
    Cho BC; Lee JS; Wu YL; Cicin I; Dols MC; Ahn MJ; Cuppens K; Veillon R; Nadal E; Dias JM; Martin C; Reck M; Garon EB; Felip E; Paz-Ares L; Mornex F; Vokes EE; Adjei AA; Robinson C; Sato M; Vugmeyster Y; Machl A; Audhuy F; Chaudhary S; Barlesi F
    J Thorac Oncol; 2023 Dec; 18(12):1731-1742. PubMed ID: 37597750
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Breakthrough Symptoms Remain an Unmet Need in Symptomatic Patients With Neuroendocrine Tumors and Carcinoid Syndrome.
    Liu E; Hoffman KD; Murfin G; Eccard H
    Pancreas; 2023 Jan; 52(1):e70-e74. PubMed ID: 37378902
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Immunogenic cell death after combined treatment with radiation and ATR inhibitors is dually regulated by apoptotic caspases.
    Eek Mariampillai A; Hauge S; Kongsrud K; Syljuåsen RG
    Front Immunol; 2023; 14():1138920. PubMed ID: 37346039
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Correlation exploration among CT imaging, pathology and genotype of pulmonary ground-glass opacity.
    Cai Y; Chen T; Zhang S; Tan M; Wang J
    J Cell Mol Med; 2023 Jul; 27(14):2021-2031. PubMed ID: 37340599
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Risk profiles and a concise prediction model for lymph node metastasis in patients with lung adenocarcinoma.
    Liang S; Huang YY; Liu X; Wu LL; Hu Y; Ma G
    J Cardiothorac Surg; 2023 Jun; 18(1):195. PubMed ID: 37340322
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. CT-based radiomics models may predict the early efficacy of microwave ablation in malignant lung tumors.
    Zhu F; Yang C; Xia Y; Wang J; Zou J; Zhao L; Zhao Z
    Cancer Imaging; 2023 Jun; 23(1):60. PubMed ID: 37308918
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 13.